Comprehensive autoantibody profiles in systemic sclerosis: Clinical cluster analysis.

Area of Science:

• Immunology
• Rheumatology
• Connective tissue diseases

Background:

• Systemic sclerosis (SSc) is a connective tissue disease characterized by specific autoantibodies.
• The role of these autoantibodies in pathogenesis and their association with clinical manifestations are areas of ongoing research.
• Understanding the autoantibody profile in SSc is crucial for clarifying disease associations and potential pathophysiological roles.

Purpose of the Study:

• To comprehensively analyze the serum autoantibody status in patients with Systemic Sclerosis (SSc).
• To correlate detected autoantibodies with the clinical course and manifestations of SSc.
• To identify distinct immunological clusters and their associated clinical phenotypes in SSc patients.

Main Methods:

• Serum samples from 372 SSc patients were analyzed for SSc-related autoantibodies using line blot and ELISA.
• Autoantibodies including centromere, Topo-1, AMA-M2, AT1R, and ETAR were quantified.
• Principal component analysis (PCA) was employed to form immunological clusters and associate them with clinical characteristics.

Main Results:

• Four distinct immunological clusters were identified in SSc patients.
• Specific autoantibodies like centromere, Topo-1, and RP3 formed clusters associated with unique clinical phenotypes.
• Patients with limited cutaneous SSc within the Topo-1 cluster showed an increased risk of interstitial lung disease.
• AMA-M2 antibodies were associated with an increased risk of cardiovascular events in SSc patients.

Conclusions:

• The autoantibody profile in Systemic Sclerosis patients provides significant clues to disease manifestation, comorbidities, and complications.
• Line blot analysis is a reliable method for detecting a broad range of autoantibodies in SSc, including rarer ones.
• Immunological clustering based on autoantibody status aids in understanding SSc heterogeneity and predicting clinical outcomes.